IMV Price/Book
Cos'è Price/Book di IMV?
Price/Book di IMV, Inc. è -2.81
Qual è la definizione di Price/Book?
Il rapporto Price to book rappresenta il rapporto tra il valore delle azioni di una società e il valore contabile per azione.
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
Price/Book di aziende nel Health Care settore su TSX rispetto a IMV
Cosa fa IMV?
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Aziende con price/book simili a IMV
- iHeartMedia ha Price/Book di -2.82
- Futuris Co ha Price/Book di -2.82
- Guyana Goldstrike ha Price/Book di -2.82
- Sakthi Sugars ha Price/Book di -2.82
- ThermoGenesis Inc ha Price/Book di -2.82
- AEON Stores (Hong Kong) Co ha Price/Book di -2.81
- IMV ha Price/Book di -2.81
- Spentex Industries ha Price/Book di -2.81
- Bausch Health Companies Inc ha Price/Book di -2.76
- Environmental Waste International ha Price/Book di -2.75
- Emerald Inc ha Price/Book di -2.74
- DXI ha Price/Book di -2.73
- IMV ha Price/Book di -2.70